Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are correct. Sorry about my mistake.
At least for today (at this time) the price drop is because of the dividend pay-out. The stock is at $3.54, down $0.12 with the dividend having been paid of $0.12 per share this morning. So essentially it is trading even for the day.
W@G2 11/14/12 for a 11/16/12 close
63.79 Kookiekook
61.65 TFO
W@G1 11/12/12 for a 11/14/12 close
64.63 TFO
63.89 Kookiekook
Good W@G Ray
Unfortunately not the only reason. Jewel-Osco unveiled a new web-site yesterday, but apparently did not test it out adequately. You can not pull up information on stores, sales, or other information. Not only will this result in loss of store sales, it is another indication of the weak management of this organization.
W@G2 11/07/12 for a 11/09/12 close
66.37 Kookiekook
64.50 rayrohn
W@G1 11/05/12 for a 11/07/12 close
66.11 Kookiekook
65.85 TFO
HEB - While there is an increase in loss as stated by HCHO, it is important to know the cause of the increase also. In this case about 60% of the increase loss is due to a change in valuation of the warrants that were previously issued. As the price of the stock changes the value of these securities change because the chances of the warrnts being excercised change.
W@G2 10/31/12 for a 11/01/12 close
64.47 Kookiekook
63.83 TFO
Per my Brokers Web-site:
Customer Service Alert
Due to severe weather in the New York area, US equity and option markets as well as futures equity index markets
will be closed on Monday, October 29, 2012.
NYSE details
NASDAQ details
CME details
ICE details
Per my Broker's Website
Customer Service Alert
Due to severe weather in the New York area, US equity and option markets as well as futures equity index markets
will be closed on Monday, October 29, 2012.
NYSE details
NASDAQ details
CME details
ICE details
W@G1 10/29/12 for a 10/31/12 close
64.14 Kookiekook
63.23 TFO
W@G2 10/24/12 for a 10/26/12 close
66.23 Kookiekook
Ray can still recieve PM's, but he can not send (or reply to) PM's. So if you misplace his e-mail adress, you can still contact him privately and if you include your e-mail adress he can respond through that medium.
W@G1 10/22/12 for a 10/24/12 close
66.23 TFO
65.79 Kookiekook
Good W@G Ray
Good W@G Fastone
W@G2 10/17/12 for a 10/19/12 close
68.55 TFO
67.69 Kookiekook
W@G1 10/15/12 for a 10/17/12 close
67.13 TFO
66.46 rayrohn
66.26 Kookiekook
Thank you Fred
Thank you Paul
Thank you Ray
Good W@G Ray
W@G2 10/10/12 for a 10/12/12 close
66.59 Kookiekook
W@G1 10/08/12 for a 10/10/12 close
69.75 TFO
69.38 Kookiekook
Be careful not to bite off more than that you handle confortably. While I can understand the need or desire to change some aspects of the contest, it does not matter as much as losing the contest completely because you burn yourself out.
As far as going to a set porfolio size (be it $25K, 100K or even $1MM) it will be wise to limit the number of stocks that can be held at anyone time to limit the work needed to track things.
NPSP - Excerpt from Standards and Poor's Stock Report dated 10-6-2012
Highlights
We see revenues of $131 million in 2012 and
$180 million in 2013, consisting mostly of royalties
from Sensipar and Preotact, from which
NPSP is repaying non-recourse debt.We assume
a U.S. approval for Gattex in late 2012,
and launch in early 2013.We project its sales
near $60 million in 2013.We no longer anticipate
approval or initial sales of Natpara in 2013,
after NPSP delayed its filing forecast to mid-
2013, from a prior late-2012 outlook.
In our view, NPSP is likely to incur significant
near-term operating expenses due to drug
pipeline and pre-commercial infrastructure investments.
However, we see near-term cash
flows enhanced by a July 2012 amendment to
its deal with Amgen that will enable NPSP to
repay an advance on Sensipar royalties over a
longer period. After this amendment, we expect
Sensipar royalties to return to NPSP in 2015,
compared with a prior 2013 outlook.
We estimate a per-share loss of $0.30 in 2012
and EPS of $0.04 in 2013. As of June 30, 2012,
NPSP had $110 million in cash, before a $25 million
payment for the sale of some royalty rights
received in July 2012.
Investment Rationale/Risk
Our strong buy opinion reflects a positive outlook
for NPSP's rare disease focused drug
pipeline.We anticipate FDA approval for lead
candidate Gattex for short bowel syndrome
near the end of 2012, after the FDA extended its
review to December 30.We are encouraged by
the drug's September 2012 approval in Europe
(marketed as Revestive), and see its orphan
drug status and our view of limited treatment
options supporting this outlook. Although we
see a biologics license application filing for
Natapara for hypoparathyroidism delayed to
mid-2013 for revised testing of its injection pen
device, we expect a favorable regulatory path.
Risks to our recommendation and target price
include failure to gain U.S. regulatory approval
for Gattex or Natpara, and a slowdown in Sensipar
sales royalties, which could slow the rate
of debt repayment.
Our 12-month target price of $13 applies a 25X
multiple to our 2014 EPS estimate of $0.65, discounted
one period at 25%, reflecting an
above-industry average risk profile, as we see
NPSP as being reliant on drug approvals to
reach profitability.
NPSP - Excerpt from Standards and Poor's Stock Report dated 10-6-2012
Highlights
We see revenues of $131 million in 2012 and
$180 million in 2013, consisting mostly of royalties
from Sensipar and Preotact, from which
NPSP is repaying non-recourse debt.We assume
a U.S. approval for Gattex in late 2012,
and launch in early 2013.We project its sales
near $60 million in 2013.We no longer anticipate
approval or initial sales of Natpara in 2013,
after NPSP delayed its filing forecast to mid-
2013, from a prior late-2012 outlook.
In our view, NPSP is likely to incur significant
near-term operating expenses due to drug
pipeline and pre-commercial infrastructure investments.
However, we see near-term cash
flows enhanced by a July 2012 amendment to
its deal with Amgen that will enable NPSP to
repay an advance on Sensipar royalties over a
longer period. After this amendment, we expect
Sensipar royalties to return to NPSP in 2015,
compared with a prior 2013 outlook.
We estimate a per-share loss of $0.30 in 2012
and EPS of $0.04 in 2013. As of June 30, 2012,
NPSP had $110 million in cash, before a $25 million
payment for the sale of some royalty rights
received in July 2012.
Investment Rationale/Risk
Our strong buy opinion reflects a positive outlook
for NPSP's rare disease focused drug
pipeline.We anticipate FDA approval for lead
candidate Gattex for short bowel syndrome
near the end of 2012, after the FDA extended its
review to December 30.We are encouraged by
the drug's September 2012 approval in Europe
(marketed as Revestive), and see its orphan
drug status and our view of limited treatment
options supporting this outlook. Although we
see a biologics license application filing for
Natapara for hypoparathyroidism delayed to
mid-2013 for revised testing of its injection pen
device, we expect a favorable regulatory path.
Risks to our recommendation and target price
include failure to gain U.S. regulatory approval
for Gattex or Natpara, and a slowdown in Sensipar
sales royalties, which could slow the rate
of debt repayment.
Our 12-month target price of $13 applies a 25X
multiple to our 2014 EPS estimate of $0.65, discounted
one period at 25%, reflecting an
above-industry average risk profile, as we see
NPSP as being reliant on drug approvals to
reach profitability.
While I understand that people want to win, it is just a contest. While someone(s) might manipulate the contest, it really doesn't benefit anyone doing that other than to gain a little limelight and some accolades. Changing the rules will reduce that somewhat but I prefer using the contest to hone my skills in picking stocks for 2-3 month gain in reference to the overall market. Winning this contest is secondary compared to winning in the market.
Good W@G Fastone. You seem to be on a roll.
He is asking "how many shares are you trying to sell?" and whether it is free selling shares (i.e. able to be sold on the market). According to my information, the current open market bid price for MKRO is $0.10/share.
Good W@G FastOne
W@G2 10/03/12 for a 10/05/12 close
69.33 Kookiekook
69.09 TFO
67.00 rayrohn
W@G1 10/01/12 for a 10/03/12 close
69.36 TFO
68.83 Kookiekook
Thank you Ray
Thank you Paul
PTN - I would not expect any meaningful movement until after the Shareholder meeting tommorrow. Than I anticipate it increasing in price to the low 90's before Oct's catalyst is announced.
Good W@G Paul
W@G2 09/26/12 for a 09/28/12 close
70.00 Farooq
68.16 Kookiekook
67.25 rayrohn